|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.40 EUR | +0.65% |
|
+6.94% | +5.48% |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| 06-10 | Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,043 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 4.11% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,599 | 1,655 | 1,828 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 14.53% | 3.5% | 10.43% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -8.21x | -9.75x | -13.5x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 3.83x | 4.11x | 4.07x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.6x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.55x | 3.43x | 2.7x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.56x | 2.78x | 2.42x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -6.58x | -10.4x | -27.5x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -6.18x | -9.53x | -21.3x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -9.1x | -14.3x | -26x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -11% | -7% | -3.84% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.215 | -1.865 | -1.347 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 448.7 | 595.6 | 755.9 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -243 | -159.9 | -66.57 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -258.7 | -173.7 | -85.83 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -240.9 | -156.5 | -125.8 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -443.1 | -387.2 | -214.4 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 18.18 | 18.18 | 18.18 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,355 | - | - |
| Announcement Date | 3/1/22 A | 3/1/23 A | 2/27/24 A | 2/27/25 A | 2/26/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.79x | 3.41x | 9.2x | 0.64% | 62.05B | |
| 26.92x | 5.45x | 15.93x | 0.59% | 54.52B | |
| 33.97x | 11.5x | 21.69x | -.--% | 41.55B | |
| -52.51x | 3.11x | 9.2x | 3.5% | 39.06B | |
| 31.74x | 3.42x | 10.51x | -.--% | 29.02B | |
| -7.4x | 10.45x | -6.37x | -.--% | 25.38B | |
| 14.83x | 2.6x | 8.05x | -.--% | 19.62B | |
| 47.78x | 5.2x | 36.07x | -.--% | 16.89B | |
| 24.64x | 5.1x | 13.75x | -.--% | 15.89B | |
| Average | 15.08x | 5.58x | 13.11x | 0.53% | 33.78B | |
| Weighted average by Cap. | 13.26x | 5.57x | 12.60x | 0.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
